The following is a summary of “Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment ...

discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib (Cabometyx) depending on whether they were pancreatic NETs (pNETs) or extrapancreatic NETs (epNETs). Results from the ...

The FCI Assistant Grade 3 Previous Year Question Papers provide candidates with an opportunity to practice questions of a similar difficulty level as the actual exam. Download the FCI Assistant Grade ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center. The new trial will test the novel combination of immunotherapy ...

The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic ...

While a persistent, low-grade ... solid tumors undergoing intravenous chemotherapy. Oncol Res Treat. 2020;43(11):605–612. doi:10.1159/000506109 Foggo V, Cavenagh J. Malignant causes of fever of ...

2-Keto-3-ethoxybutyraldehyde bis(thiosemicarbazone) (KTS) has been shown to have marked carcinostatic and carcinolytic activity against several established rat tumors ...

The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic ...